Expression Pathology, Inc. has now closed $850,000 of a $1.2 million Series A Preferred offering and is in due diligence with additional investors. EPI was chosen as the company 'Most Likely to Receive Funding' at Bio-Life-Tech Princeton.
For more information on Expression Pathology, Inc. please visit their website at www.expressionpathology.com.
Volume
1, Issue 2
February 12, 2007
ESE's Bio Life Tech conference provided an excellent opportunity to hone the company's message with great coaching and practice sessions, and good networking opportunities.
Casey Eitner President & CEO Expression Pathology
To remove your name from our
mailing list, please click
here.
Questions or comments? E-mail us at [email protected] or call
(302) 777-2460.
